| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00183404 | Autism | Drug: Olanzapine | Drexel University|National Institute of Mental Health (NIMH) | Phase 2|Phase 3 | 2004-09-01 | 2014-08-14 |
| NCT03066622 | Headache | Drug: Standard of Care as per attending physician|Drug: 5mg rapidly dissolving olanzapine | HealthPartners Institute | | 2016-07-01 | 2017-02-23 |
| NCT01184443 | Eating Disorder | Drug: Olanzapine | Children's Hospital of Eastern Ontario | Phase 3 | 2010-08-01 | 2014-09-03 |
| NCT02129478 | Chemotherapy-induced Nausea and Vomiting | Drug: Olanzapine | The Hospital for Sick Children|Pediatric Oncology Group of Ontario | Phase 2 | 2014-03-01 | 2016-09-26 |
| NCT01625923 | Idiopathic Gastroparesis | Drug: Olanzapine | University of Michigan|Massachusetts General Hospital | | 2013-01-01 | 2016-06-30 |
| NCT01503424 | Fed | Drug: Olanzapine | Dr. Reddy's Laboratories Limited | Phase 1 | 2011-08-01 | 2012-01-04 |
| NCT01503398 | Fasting | Drug: Olanzapine | Dr. Reddy's Laboratories Limited | Phase 1 | 2011-08-01 | 2012-01-04 |
| NCT00287352 | Psychotic Disorder|Schizophreniform Disorder|Schizophrenia|Schizoaffective Disorder|Mood Disorders With Psychotic Features | Drug: Olanzapine, Amantadine|Drug: Olanzapine and placebo | University of North Carolina, Chapel Hill|Eli Lilly and Company | Phase 1 | 2005-05-01 | 2011-04-29 |
| NCT00678457 | Alcohol Dependence | Drug: Ondansetron|Drug: Olanzapine|Drug: Placebo | University of Virginia | Phase 2 | 2007-01-01 | 2009-01-29 |
| NCT00275301 | Borderline Personality Disorder | Drug: olanzapine | University of Minnesota - Clinical and Translational Science Institute|Eli Lilly and Company | | 2005-12-01 | 2011-08-25 |
| NCT01503450 | Fed | Drug: Olanzapine OD Tablets 5 mg | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-11-01 | 2012-01-04 |
| NCT01503437 | Fasting | Drug: Olanzapine OD Tablets 5 mg | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-11-01 | 2012-01-04 |
| NCT00273624 | Therapy-resistant Depression | Drug: Olanzapine|Drug: Placebo | University Hospital Freiburg | Phase 3 | 2005-06-01 | 2016-05-12 |
| NCT00568672 | Relapse Rate of a Major Depressive Episode|Safety of Olanzapine in Subjects With Major Depression | Drug: Olanzapine | Charite University, Berlin, Germany|Eli Lilly and Company | Phase 3 | 2007-10-01 | 2008-04-23 |
| NCT02435654 | Early-onset Schizophrenia | Drug: olanzapine | Kunming Medical University|National Natural Science Foundation of China | Phase 4 | 2015-08-01 | 2016-11-30 |
| NCT02970643 | Chemotherapy-induced Nausea and Vomiting | Drug: Olanzapine|Drug: Palonosetron | Hee Jun Kim|CJ HealthCare Corporation|Chung-Ang University Hosptial, Chung-Ang University College of Medicine | | 2016-07-01 | 2016-11-22 |
| NCT00088465 | Schizophrenic Disorders|Schizoaffective Disorder | Drug: Intramuscular olanzapine depot | Eli Lilly and Company | Phase 3 | 2004-08-01 | 2011-12-09 |
| NCT00320489 | Schizophrenia | Drug: olanzapine|Drug: olanzapine pamoate depot | Eli Lilly and Company | Phase 3 | 2006-04-01 | 2012-01-19 |
| NCT00260962 | Anorexia Nervosa | Drug: Olanzapine | Ottawa Hospital Research Institute|Eli Lilly and Company | Phase 2 | 2000-09-01 | 2009-09-30 |
| NCT00636896 | Weight Gain | Drug: Olanzapine plus modafinil|Drug: Olanzapine plus placebo | Neuropsychiatric Research Institute, Fargo, North Dakota|Eli Lilly and Company|University of North Dakota | | 2006-07-01 | 2008-03-10 |
| NCT00194064 | Bipolar Disorder | Drug: Olanzapine | University Hospitals Cleveland Medical Center|Eli Lilly and Company | Phase 3 | 2002-07-01 | 2016-10-03 |
